Short communication: Analysis of the integrase gene from HIV type 1-positive patients living in a rural area of west cameroon

AIDS Research and Human Retroviruses

Volumn 28, Issue 12, 2012, Pages 1729-1733

  Turriziani, Ombretta ^a   Montagna, Claudia ^a   Falasca, Francesca ^a   Bucci, Mauro ^a   Russo, Gianluca ^a   Lichtner, Miriam ^a   Sobze, Martin Sanou ^b   Vullo, Vincenzo ^a   Pistello, Mauro ^c   Antonelli, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF DSCHANG   (Cameroon)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CAMEROON; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PRIORITY JOURNAL; RURAL AREA; VIRUS LOAD;

CAMEROON; CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; MOLECULAR EPIDEMIOLOGY; MUTATION, MISSENSE; PHYLOGENY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RURAL POPULATION; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY;

EID: 84870009755     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0266     Document Type: Article

References (27)

1. Pommier Y, Johnson AA, and Marchand C: Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005;4:236-248.
2. Cooper DA, Steigbigel RT, Gatell JM, et al.: BENCHMRK Study Teams: Subgroup and resistance analyses of ralte-gravir for resistant HIV-1 infection. N Engl J Med 2008;359:355-365.
3. Malet I, Delelis O, Valantin MA, et al.: Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008;52:1351-1358.
4. Hazuda DF, Miller MD, Nguyen By, et al.: Resistance to the HIV-integrase inhibitor raltegravir: Analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1 infection. Antivir Ther 2007;12:S10.
5. Canducci F, Sampaolo M, Marinozzi MC, et al.: Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 2009;23:455-460.
6. Jones G, Ledford R, Yu F, Miller M, Tsiang M, and McDoll D: Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303) [abstract 627]. In:14th Conference on Retroviruses and Opportunistic Infection, Los Angeles, CA, 2007. February 25-28, 2007.
7. McColl D, Fransen S, Gupta S, et al.: Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137) [abstract 9]. Antivir Ther 2007;12:S11.
8. Low A, Prada N, Topper M, et al.: Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother 2009;53:4275-4282.
9. Turriziani O, Bucci M, Stano A, et al.: Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. J Acquir Immune Defic Syndr 2007;44:518-524.
10. Paar C, Palmetshofer C, Flieger K, et al.: Genotypic anti-retroviral resistance testing for human immunodeficiency virus type 1 integrase inhibitors by use of the TruGene sequencing system. J Clin Microbiol 2008;46:4087-4090.
11. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, and Kumar S: MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011;28(10):2731-2739.
12. Tamura K, Nei M, and Kumar S: Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc Natl Acad Sci USA 2004;101:11030-11035.
13. Zuckerkandl E and Pauling L: Evolutionary divergence and convergence in proteins. In: Evolving Genes and Proteins (Bryson V and Vogel HJ, eds.). Academic Press, New York, 1965, pp. 97-166.
14. Saitou N and Nei M: The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol Biol Evol 1987;4:406-425.
15. Tamura K and Nei M: Estimation of the number of nucleo-tide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 1993; 10:512-526.
16. Felsenstein J: Confidence limits on phylogenies: An approach using the bootstrap. Evolution 1985;39:783-791.
17. Johnson VA, Brun-Vézinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010;18:156-163.
18. Brenner BG, Lowe M, Moisi D, et al.: Subtype diversity associated with the development of HIV-1 resistance to in-tegrase inhibitors. J Med Virol 2011;83:751-759.
19. Fish MQ, Hewer R, Wallis CL, Venter WD, Stevens WS, and Papathanasopoulos MA: Natural polymorphisms of in-tegrase among HIV type 1-infected South African patients. AIDS Res Hum Retroviruses 2010;26:489-493.
20. Brennan CA, Bodelle P, Coffey R, et al.: The prevalence of diverse HIV-1 strains was stable in Cameroonian blood donors from 1996 to 2004. J Acquir Immune Defic Syndr 2008;49:432-139.
21. Tsurutani N, Kubo M, Maeda Y, et al.: Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells. J Virol 2000;74:4795-4806.
22. Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, and Perno CF: Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009; 11:17-29.
23. Rhee SY, Liu TF, Kiuchi M, et al.: Natural variation of HIV-1 group M integrase: Implications for a new class of anti-retroviral inhibitors. Retrovirology 2008;5:74.
24. Maïga AI, Malet I, Soulie C, et al.: Genetic barriers for in-tegrase inhibitor drug resistance in HIV type-1 B and CRF02-AG subtypes. Antivir Ther 2009;14:123-129.
25. Suzuki H, Fujino M, Matsuda M, Yen H, Iwantani Y, and Sugiura W: Effects of protease and reverse transcriptase inhibitors resistance mutations on integrase polymorphism in multidrug resistance cases. Antivir Ther 2007;12:S4.
26. van Hal SJ, Herring B, Deris Z, Wang B, Saksena NK, and Dwyer DE: HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure. Retrovirology 2009;6:12.
27. Van Baelen K, Van Eygen V, Rondelez E, and Stuyver LJ: Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS 2008;22:1877-1880.